Crystalline forms of a quinazoline compound and its hydrochloride salts

1. Crystalline form of a compound of Chemical formula (1):

wherein the chemical purity of the crystalline form is greater than about 80%, and

wherein the crystalline form is selected from the group consisting of

(a) a dihydrate (2H 2 O) crystalline form of the compound of Chemical Formula (1) and the crystalline form, wherein the dihydrate crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at diffraction angle 2θ values of 9.4°±0.2°, 13.0°±0.2° and 18.5°±0.2° when irradiated with a Cu-Kα light source;

(b) an anhydrous Form I of the compound of Chemical Formula (1), wherein the anhydrous Form I has an XRPD pattern comprising peaks at diffraction angle 2 values θ of 6.0°±0.2°, 18.3°±0.2° and 22.7°±0.2° when irradiated with a Cu-Kα light source;

(c) an anhydrous Form II of the compound of Chemical Formula (1), wherein the anhydrous Form II has an XRPD pattern comprising peaks at diffraction angle 20 values of 4.9°±0.2°, 5.9°±0.2° and 11.8°±0.2° when irradiated with a Cu-Kα light source;

(d) a monohydrochloride monohydrate (1HCl·1H 2 O) crystalline form of the compound of Chemical Formula (1), wherein the monohydrochloride monohydrate crystalline form has an XRPD pattern comprising peaks at diffraction angle 2θ values of 8.9°±0.2°, 13.4°±0.2°, 21.1°±0.2° and 23.5°±0.2° when irradiated with a Cu-Kα light source; and

(e) an anhydrous monohydrochloride crystalline form of the compound of Chemical Formula (1), wherein the anhydrous monohydrochloride crystalline form has an XRPD pattern comprising peaks at diffraction angle 2 values θ of 9.5°±0.2°, 23.0°±0.2°, 23.2°±0.2° and 23.5°±0.2° when irradiated with a Cu-Kα light source.

2. The crystalline form of the compound of Chemical formula (1) of claim 1 , wherein the chemical purity of the crystalline form is greater than 95%.

3. The crystalline form of claim 1 , wherein the crystalline form is as described in (a).

4. The crystalline form of claim 1 , therein the crystalline form is as described in (b).

5. The crystalline form of claim 1 , wherein the crystalline form is as described in (c).

6. The crystalline form of claim 1 , wherein the crystalline form is as described in (d).

7. The crystalline form of claim 1 , wherein the crystalline form is as described in (e).

8. The crystalline form of claim 1 , wherein the crystalline form is as described in (a), and wherein the crystalline form has a 13 C solid state nuclear magnetic resonance (ssNMR) spectrum comprising peaks at the following chemical shifts: 147.7±0.5, 156.2±0.5 and 165.4±0.5 ppm.

9. The crystalline form of claim 1 , wherein the crystalline form is as described in (b), and wherein the crystalline form has a 13 C ssNMR spectrum comprising peaks at the following chemical shifts: 54.3±0.5, 127.3±0.5, 146.9±0.5 and 156.7±0.5 ppm.

10. The crystalline form of claim 1 , wherein the crystalline form is as described in (c), and wherein the crystalline form has a 13 C ssNMR spectrum comprising peaks at the following chemical shifts: 129.2±0.5, 153.1±0.5, 156.7±0.5 and 165.2±0.5 ppm.

11. The crystalline form of claim 1 , wherein the crystalline form is as described in (d), and wherein the crystalline form has a 13 C ssNMR spectrum comprising peaks at the following chemical shifts: 145.8±0.5, 157.8±0.5 and 164.5±0.5 ppm.

12. The crystalline form of claim 1 , wherein the crystalline form is as described in (e), and wherein the crystalline form has a 13 C ssNMR spectrum comprising peaks at the following chemical shifts: 146.9±0.5, 158.7±0.5 and 163.0±0.5 ppm.

13. A pharmaceutical composition comprising the crystalline form of claim 1 , and at least one pharmaceutically acceptable carrier or diluent.

14. The pharmaceutical composition of claim 13 , wherein the chemical purity of the crystalline form is greater than about 95%.

15. The pharmaceutical composition of claim 13 , further comprising a non-metallic salt lubricant selected from the group consisting of glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl trimyristate, glyceryl tristearate, sucrose fatty acid ester, palmitic acid, palmitoyl alcohol, stearic acid, stearyl alcohol, fumaric acid, polyethyleneglycol 4000, polyethyleneglycol 6000, polytetrafluoroethylene, starch, talc, hydrogenated castor oil, mineral oil, hydrogenated vegetable oil, silicon dioxide, and any combination thereof.

16. The pharmaceutical composition of claim 13 , further comprising a metallic salt lubricant.

17. A method of treating a cancer in a subject comprising administering to the subject the pharmaceutical composition of claim 13 , wherein the cancer is selected from the group consisting of non-small cell lung cancer, oral cancer, oropharyngeal cancer, nasopharyngeal cancer, respiratory cancer, urogenital cancer, gastrointestinal cancer, central or peripheral nervous system tissue cancer, an endocrine or neuroendocrine cancer or hematopoietic cancer, glioma, sarcoma, carcinoma, lymphoma, melanoma, fibroma, meningioma, brain cancer, oropharyngeal cancer, nasopharyngeal cancer, renal cancer, biliary cancer, pheochromocytoma, pancreatic islet cell cancer, Li-Fraumeni tumors, thyroid cancer, parathyroid cancer, pituitary tumors, adrenal gland tumors, osteogenic sarcoma tumors, multiple neuroendocrine type I and type II tumors, breast cancer, lung cancer, head and neck cancer, prostate cancer, esophageal cancer, tracheal cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer and skin cancer.

18. The method of claim 17 , wherein the cancer is non-small cell lung cancer.

19. A method of preparing the crystalline form of the compound of Chemical formula of claim 1 , comprising

(1) preparing the dihydrate (2H 2 O) of claim 3 , comprising:

(a) adding the compound of Formula 1 to a mixture of acetone and water, wherein the acetone and the water are in such a ratio that the compound cannot completely dissolve in the mixture at room temperature;

(b) heating the mixture to a temperature wherein the compound completely dissolves; and

(c) cooling down the mixture and removing the acetone and water to obtain the dihydrate (2H 2 O) of the compound;

(2) preparing the anhydrous Form I of claim 4 , comprising:

(a) mixing the dihydrate (2H 2 O) of the compound of claim 3 with acetone; and

(b) isolating the anhydrous Form I of the compound;

(3) preparing the anhydrous Form II of claim 5 , comprising:

(a) mixing the anhydrous Form I of the compound of claim 4 with acetonitrile;

(b) heating to above about 80° C.; and

(c) cooling down and isolating the anhydrous Form II of the compound;

(4) preparing the monohydrochloride monohydrate (1HCl·1H 2 O) of claim 6 , comprising:

(a) mixing the compound of Formula 1 with ethanol, water and aqueous hydrochloric acid; and

(b) isolating the monohydrochloride monohydrate (1HCl·1H 2 O) of the compound; or

(5) preparing the anhydrous monohydrochloride crystalline form of claim 7 , comprising:

(a) mixing an anhydrous compound of formula 1 with a non-protic polar solvent and a hydrochloric acid having a concentration of about 30% or more; and

(b) isolating the anhydrous monohydrochloride of the compound.

20. The method of claim 19 , comprising preparing the anhydrous monohydrochloride crystalline form of claim 7 , wherein non-protic polar solvent is DMSO or DMF.

21. A kit comprising the crystalline form of claim 1 , and at least one cytotoxic agent and/or at least one molecularly targeted agent, as the active ingredient, wherein the at least one cytotoxic agent is selected from the group consisting of taxanes, base analogs, VEGF inhibitors, platinum-based antineoplastic drugs and vinca alkaloids, and wherein the at least one molecularly targeted agent is selected from the group consisting of at least one epidermal growth factor receptor (EGFR) family inhibitor.